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Abstract
Background: To investigate the 3-month postoperative performance and safety after implantation of a trifocal
intraocular lens (IOL) in a Korean population.
Methods: This was a clinical, prospective, multicenter, single-arm study. Forty-four subjects (88 eyes) with bilateral
cataract with expected postoperative corneal astigmatism of < 1.00 diopter (D) and no ocular disease or eye
condition underwent bilateral implantation of the AcrySof IQ® PanOptix IOL (TFNT00). Postoperative examination at
3 months included binocular defocus curve; binocular best corrected distance visual acuity (BCDVA); monocular/
binocular uncorrected VA (UCVA) at distance (4 m), intermediate (60 cm), and near (40 cm); contrast sensitivity under
photopic conditions with/without glare; and subjective outcomes, including satisfaction and spectacle
independence.
Results: Binocular defocus curve at 3 months after bilateral implantation showed VA of 0.1 logMAR or better from
+ 0.5 D through − 2.5 D. Binocular BCDVA mean ± SD at 4 m was − 0.05 ± 0.07 logMAR. Binocular and monocular
UCVA was 0.03 ± 0.1 and 0.08 ± 0.12 logMAR (4 m), − 0.00 ± 0.11 and 0.05 ± 0.13 logMAR (60 cm), and 0.03 ± 0.12
and 0.09 ± 0.13 logMAR (40 cm), respectively. Contrast sensitivity with glare was 1.67 ± 0.13, 1.91 ± 0.17, 1.54 ± 0.21,
and 1.14 ± 0.20 log units at 3, 6, 12, and 18 cycles/degree, respectively. At near and intermediate distances, 84 and
77% of subjects reported good/excellent satisfaction, and 84 and 91% of subjects reported spectacle independence,
respectively.
Conclusions: In a Korean population, visual performance of the trifocal TFNT00 IOL 3months postoperatively was
< 0.1 logMAR for binocular UCVA at all distances, with high subject satisfaction and spectacle independence.
Trial registration: www.ClinicalTrials.gov (NCT03268746). Registered August 31, 2017.
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Background
Many subjects who receive monofocal intraocular lenses
(IOLs) ultimately require corrective glasses after cataract
surgery to improve their intermediate or near distance
vision [1]. Most multifocal IOLs can produce 2 foci for
distance and near vision, providing a more complete
range of vision compared with monofocal IOLs [2, 3];
however, glasses may be needed for intermediate vision
[3, 4]. Because many daily activities, such as viewing
computer or smartphone screens, are performed at
intermediate distances [5, 6], trifocal IOLs with 3 focal
points have been developed to address the need for
improved intermediate vision after cataract surgery [7].
The first generation of trifocal IOLs, including AT
LISA® tri 839MP (Carl Zeiss Meditec, Jena, Germany)
and FineVision® Micro F (PhysIOL, Liège, Belgium),
has an intermediate focal point at 80 cm [8, 9]. How-
ever, for many people, the optimal distance for daily
intermediate vision tasks is at arm’s length, approxi-
mately 60 to 70 cm for populations of average height
[6, 10]. The AcrySof® IQ PanOptix® IOL model
TFNT00 (Alcon Vision LLC, Fort Worth, TX, USA)
has near and distance focal points similar to a con-
ventional multifocal IOL and an intermediate focal
point at 60 cm [11, 12]. In an optical bench study,
TFNT00 provided better image quality at intermediate
distance compared with either AT LISA tri 839MP or
FineVision Micro F because of improved light
utilization [13]. Clinical studies of TFNT00 have
shown that subjects achieved visual acuity (VA) of
20/25 or better from near (40 cm) through intermedi-
ate distance (60 cm) 6 to 12 months after IOL im-
plantation [14–16]. The results of these studies
indicate that the 60-cm focal point may provide opti-
mal intermediate vision compared with the 80-cm
focal point of earlier-generation trifocal IOLs.
The popularity of cataract surgery and IOL implantation
has increased in Korea over the past decade, and multi-
focal IOLs are the most frequently selected lenses [17].
The TFNT00 IOL may provide good VA at intermediate
distance for Korean subjects, for whom average arm
length is between 53 and 59 cm [18, 19]; however, no clin-
ical studies have been conducted in this population.
The purpose of this study was to evaluate the safety and
effectiveness of TFNT00 in a Korean population 3months
after implantation, including visual performance, quality
of vision, and subject satisfaction of postoperative vision.
Methods
Intraocular Lens
The TFNT00 IOL is intended for implantation in the
capsular bag to correct presbyopia after cataract sur-
gery [12]. TFNT00 is a single-piece, ultraviolet-
absorbing, and blue-light-filtering IOL with a 13.0-
mm overall diameter and a 6.0-mm biconvex optic.
The anterior surface of the IOL has 0.1-μm negative
spherical aberration to compensate for the positive
spherical aberration of an average cornea. The multi-
focal diffractive structure in the central 4.5-mm por-
tion of the anterior surface of the optical zone divides
incoming light to create + 2.17 diopter (D) (inter-
mediate) and + 3.25 D (near) add powers. Cataract
surgery was performed following surgeons’ routine
procedures. Clear corneal incisions (1.8 to 2.75mm) were
made either on temporal or on steep axis. After phacoe-
mulsification, implantation of the TFNT00 IOL was car-
ried out according to the local guidelines and product
information provided by Alcon Vision LLC [12].
Study design and population
This prospective, single-arm, unmasked, nonrando-
mized, multicenter study enrolled subjects aged > 20
years requiring bilateral cataract surgery. The study was
conducted at 4 sites in Korea: Samsung Medical Center
(n = 15), Asan Medical Center (n = 12), and Severance
Hospital (n = 15) in Seoul and Seoul National University
Bundang Hospital (n = 10) in Seongnam-si. Eligible
subjects were those without ocular disease that could
confound study outcomes who wanted an IOL that pro-
vided near, intermediate, and distance vision. Inclusion
criteria were clear intraocular media other than cataract
in both eyes, calculated lens power between + 16.0 D
and + 24.0 D, and preoperative or expected postoperative
regular corneal astigmatism of < 1.00 D. Exclusion
criteria were clinically significant corneal abnormalities;
previous corneal transplantation; ocular trauma; previ-
ous refractive surgery or refractive procedures through-
out the study duration; history of concurrent retinal
conditions; anterior chamber ≤2.5 mm not caused by
swollen cataract; concurrent anterior or posterior seg-
ment inflammation; and expectation of ocular surgical
treatment, large capsulotomy, or retinal laser treatment
during the study (excluding neodymium-doped yttrium
aluminum garnet [Nd:YAG] capsulotomy).
Study visits included a screening visit, an operative
visit for each eye, and postoperative visits at week 1 and
months 1 and 3. At the screening visit, the eye with
worse best corrected distance VA (BCDVA) was selected
as the first operative eye; if BCDVA was the same in
both eyes, the right eye was selected as the first operative
eye. Implantation of the IOL in the second eye occurred
within 30 days of the first eye, and according to the
standard visit schedule at each participating site.
Effectiveness endpoints
The primary endpoint was the binocular defocus
curve measured 3 months after implantation. Best dis-
tance correction was varied from − 5.00 to + 2.00 D in
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steps of 0.50 D under photopic conditions (approximately
85 cd/m2), and VA was recorded at each refractive
correction.
Secondary endpoints were the binocular defocus curve
measured 1 month after implantation, VA at 1 and 3
months after implantation, contrast sensitivity 3 months
after implantation, and responses to the subject satisfac-
tion questionnaire at the preoperative visit and 3months
after implantation. BCDVA and mean monocular and
binocular uncorrected distance VA (UCDVA, 4 m),
uncorrected intermediate VA (UCIVA, 60 cm), and
uncorrected near VA (UCNVA, 40 cm) were measured
under photopic conditions with ambient lighting lower
than chart luminance using CSV-1000 charts (distance)
and Early Treatment Diabetic Retinopathy Study charts
(distance, intermediate, and near). Photopic best
corrected binocular contrast sensitivity was measured at
3, 6, 12, and 18 cycles per degree (cpd) using CSV-1000E
charts at a distance of 2.45 m, without glare and with
glare (approximately 2.5 cd/m2).
Subjects completed a 12-item questionnaire to deter-
mine satisfaction levels and spectacle independence.
Other exploratory endpoints were photopic and mesopic
pupil size 3 months after implantation, measured with a
pupilometer to the nearest 0.5 mm at distance, and
manifest refraction spherical equivalent (MRSE) at week
1, month 1, and month 3 after implantation, measured
under photopic conditions at 2.45 m in steps of 0.25 D.
Safety analyses
Ocular nonserious and serious adverse events (AEs),
including secondary surgical interventions related to the
optical properties of the IOL, were assessed for ≤3months
after implantation and coded using the Medical Diction-
ary for Regulatory Activities Version 21.0. Additional safety
endpoints included IOL tilt/decentration, intraocular pres-
sure, surgical problems, and device deficiencies.
Statistical analyses
Binocular effectiveness was evaluated for all subjects
with successful bilateral IOL implantation (full analysis
set), monocular effectiveness was evaluated for all eyes
with successful IOL implantation (all-implanted analysis
set), and safety data were collected for all subjects with
attempted IOL implantation (safety set).
Subject demographics were summarized using descrip-
tive statistics. Effectiveness endpoints were evaluated using
a 2-sided 90% CI of the mean for VA data (logarithm of
the minimum angle of resolution [logMAR]). BCDVA and
monocular/binocular UCDVA, UCIVA, and UCNVA
were also summarized as categorical variables by visit as
percentage of subjects with 20/20, 20/25, 20/32, or 20/40
vision or better. Subjective symptom questions were
summarized by visit per question as total number of
observations and counts and percentages in each category.
AEs were summarized as counts and percentages of eyes
with ocular AEs for first and second operative eyes.
Ethics
This clinical study was conducted under an approved
Institutional Review Board protocol in accordance with
the ethical principles of the Declaration of Helsinki,
ISO14155:2011 Clinical Investigation of Medical Devices for
Human Subjects – Good Clinical Practice, and Standards
for Medical Devices for Good Clinical Practice. All subjects




Of 52 enrolled subjects, 7 discontinued the study before
IOL implantation because of screen failure. Most sub-
jects (84%) were aged < 65 years and female (Table 1).
Of the 45 subjects who received TFNT00, 1 subject
withdrew from the study after the first eye implantation
and did not receive an IOL in the second eye. The
implanted eye was included in the all-implanted and
safety analysis sets; the subject was excluded from the
full analysis set.









Height, mean (SD), cm 159.9 (8.3)
Arm length, mean (SD), cm 54.2 (6.3)
Axial length, mean (SD), mm
First eye 23.6 (0.67)
Second eye 23.6 (0.67)
Corneal astigmatism, mean (SD), D
First eye 0.62 (0.32)
Second eye 0.57 (0.25)
Monocular BCDVA, mean (SD), logMAR
First eye 0.26 (0.29)
Second eye 0.10 (0.18)
MRSE, mean (SD), D
First eye 0.36 (1.48)
Second eye 0.30 (1.57)
BCDVA Best corrected distance visual acuity, D Diopter, logMAR Logarithm of
the minimum angle of resolution, MRSE Manifest refraction
spherical equivalent
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Effectiveness
At month 3 after implantation, the binocular defocus
curve showed mean VA of 0.1 logMAR (20/25 Snellen)
or better between + 0.50 and − 2.50 D defocus (Fig. 1).
Overall, the binocular defocus curve showed that
TFNT00 provided functional VA across a full range of
distances, with most refractive steps showing better VA
at month 3 compared with month 1.
Binocular and monocular visual acuity are summarized
in Table 2. Mean binocular BCDVA decreased from
approximately 0.1 logMAR before implantation to 0.0
logMAR (20/20 Snellen) at month 1 (Fig. 2a) and month
3 (Fig. 2b) after implantation. By month 3, binocular
UCVA was 0.3 logMAR or better at distance (4 m),
intermediate (60 cm), and near (40 cm). Similarly, mon-
ocular UCVA improved from month 1 (Fig. 2c) to
month 3 (Fig. 2d). All subjects had BCDVA 20/40 or
better at month 3 compared with the preoperative visit
(Fig. 3a). Most subjects had 20/40 vision or better at
month 3 for binocular UCDVA (100%), UCIVA (100%),
and UCNVA (96%) (Fig. 3b). Mean photopic best
corrected contrast sensitivity was similar for conditions
without glare (Fig. 4a) or with glare (Fig. 4b) and was
highest for 6 cpd.
Overall, after implantation of TFNT00, subject satis-
faction was higher for near and intermediate vision
compared with distance vision (Table 3). Before surgery,
89 and 86% of subjects were dissatisfied with their near
and intermediate vision, respectively. At month 3 after
IOL implantation, 84 and 77% of subjects were satisfied
with their near and intermediate vision, respectively.
Spectacle independence for distance, intermediate, and
near vision increased by > 60% after IOL implantation.
Of the 2 subjects who reported being “very dissatisfied”
with surgery results at month 3, 1 experienced mild
posterior capsule opacification that was not resolved and
the other experienced visual impairment, conjunctivitis,
corneal edema, and dry eye.
Although the study sample size was relatively small, a
range of pupil sizes were observed in the all-implanted ana-
lysis set (Table 4). Subgroup analysis of the defocus curve
by pupil size at month 3 did not show an effect of photopic
pupil size on visual performance at any range of defocus.
After IOL implantation, mean MRSE was approxi-
mately − 0.1 D throughout the study period (Fig. 5). By
month 3, absolute residual refraction was within 0.3 D
of the target MRSE, indicating good refractive predict-
ability of TFNT00.
Safety
The most common AEs were dry eye (24%) and glare
(22%). All other AEs occurred in < 10% of subjects
Fig. 1 Binocular defocus curves 1 and 3months after implantation of TFNT00. Error bars represent 90% CI. D = diopter; logMAR = logarithm of the
minimum angle of resolution
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Table 2 Mean Binocular and Monocular Visual Acuity. (All-Implanted Analysis Set)
Mean binocular visual acuity, logMAR Month 1 Month 3
BCDVA, 4 m − 0.02 −0.05
UCDVA, 4 m 0.05 0.03
UCIVA, 60 cm 0.02 −0.03
UCNVA, 40 cm 0.05 0.03
Mean monocular visual acuity, logMAR Month 1 Month 3
First eye Second eye First eye Second eye
UCDVA, 4 m 0.09 0.10 0.07 0.08
UCIVA, 60 cm 0.08 0.08 0.05 0.04
UCNVA, 40 cm 0.12 0.10 0.09 0.09
BCDVA Best corrected distance visual acuity, logMAR Logarithm of the minimum angle of resolution, UCDVA Uncorrected distance visual acuity, UCIVA Uncorrected
intermediate visual acuity, UCNVA Uncorrected near visual acuity
Fig. 2 Binocular visual acuity (a) 1 month and (b) 3 months and monocular visual acuity at (c) 1 month and (d) 3 months after implantation of
TFNT00 (full analysis set). Error bars represent 90% CI. BCDVA = best corrected distance visual acuity; logMAR = logarithm of the minimum angle
of resolution; UCDVA = uncorrected distance VA; UCIVA = uncorrected intermediate VA; UCNVA = uncorrected near VA; VA = visual acuity
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(Table 5), and no subjects discontinued the study
because of an AE. Although halo vision occurred in 7%
of eyes, no subjects required secondary surgical interven-
tion because of halos. Two serious ocular AEs were re-
ported in 1 subject who experienced mild decentration
(2 mm) of the IOL due to capsular contraction and
subsequently underwent secondary surgical intervention
for repositioning of the IOL.
Clinically significant subjective posterior capsule opa-
cification was reported in 3 eyes of 2 subjects and was
assessed by the investigator as mild and not related to
the IOL. One eye required an Nd:YAG laser treatment
Fig. 3 Percentages of subjects with 20/40 vision or better for (a) BCDVA before implantation and 3 months after implantation of TFNT00
and (b) UCDVA, UCIVA, and UCNVA 3 months after implantation of TFNT00 (full analysis set). BCDVA = best corrected distance visual
acuity; logMAR = logarithm of the minimum angle of resolution; UCDVA = uncorrected distance VA; UCIVA = uncorrected intermediate
VA; UCNVA = uncorrected near VA
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of 2-mm-diameter posterior capsulotomy. Two nonseri-
ous ocular device AEs were reported by 2 subjects: 1
subject reported mild halo vision in both eyes that re-
solved at month 3, and 1 subject reported mild visual
impairment in both eyes that resolved without sequelae.
Discussion
Subjects who receive IOLs increasingly expect to achieve
an extended range of vision after cataract surgery [20].
Compared with a standard monofocal IOL, the trifocal
TFNT00 IOL had better corrected and uncorrected near
and intermediate VA [21] and may be a suitable choice
for subjects who want to achieve spectacle independence
after cataract surgery. In 2 large multicenter clinical
trials of TFNT00 with study sites located in Australia,
Europe, South America, and the United Kingdom,
subjects reported high levels of satisfaction with
TFNT00 in addition to improved visual outcomes for
near, intermediate, and distance vision [16]. Although
TFNT00 has been studied in western populations, it has
not been evaluated in the Korean population. Recently,
the prevalence of myopia in Korea has increased [22],
and ophthalmic evaluation surveys from 2008 to 2014
showed that 71% of Korean subjects aged < 50 years and
Fig. 4 Photopic best corrected binocular contrast sensitivity at 3 months after implantation of TFNT00 (a) without glare and (b) with glare (full
analysis set). Error bars represent 90% CI. cpd = cycles per degree
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Table 3 Responses to Subject Satisfaction Questions (Full Analysis Set)





How satisfied are you with your vision for seeing
objects at near distance?
Dissatisfied/very dissatisfied 39 (89) 3 (7)
Neither satisfied nor dissatisfied 3 (7) 4 (9)
Satisfied/very satisfied 2 (5) 37 (84)
How often do you wear eyeglasses or contact
lenses for seeing objects at near distance?
None of the time 7 (16) 37 (84)
Some of the time 7 (16) 6 (14)
Most of the time 11 (25) 0
All of the time 19 (43) 1 (2)
How satisfied are you with your vision for seeing
objects at intermediate distance?
Dissatisfied/very dissatisfied 38 (86) 5 (11)
Neither satisfied nor dissatisfied 3 (7) 5 (11)
Satisfied/very satisfied 3 (7) 34 (77)
How often do you wear eyeglasses or contact
lenses for seeing objects at intermediate
distance?
None of the time 9 (21) 40 (91)
Some of the time 12 (27) 3 (7)
Most of the time 11 (25) 0
All of the time 12 (27) 1 (2)
How satisfied are you with your vision for seeing
objects at distance?
Dissatisfied/very dissatisfied 28 (64) 4 (9)
Neither satisfied nor dissatisfied 11 (25) 9 (21)
Satisfied/very satisfied 5 (11) 31 (70)
How often do you wear eyeglasses or contact
lenses for seeing objects at distance?
None of the time 14 (32) 42 (96)
Some of the time 9 (21) 1 (2)
Most of the time 5 (11) 0
All of the time 16 (36) 1 (2)
How often do you experience halos? None of the time 10 (23) 3 (7)
Some of the time 20 (46) 11 (25)
Most of the time 10 (23) 15 (34)
All of the time 4 (9) 15 (34)
How severe were these halos? None 9 (21) 3 (7)
Mild 13 (30) 5 (11)
Moderate 15 (34) 22 (50)
Severe 7 (16) 14 (32)
If you currently drive, how much difficulty do
you have driving at night?
No difficulty at all 5 (11) 4 (9)
A little difficulty 5 (11) 5 (11)
Moderate difficulty 13 (30) 11 (25)
Extreme difficulty 11 (25) 10 (23)
I do not drive at night 10 (23) 14 (32)
If you do not drive at night, what is the reason? Because of your current eyesight 12 (27) 11 (25)
Because you are not interested in driving 5 (11) 5 (11)
Because you have other reasons 10 (23) 12 (27)
I drive at night 17 (39) 16 (36)
How satisfied are you with your cataract
surgery result?
Dissatisfied/very dissatisfied N/A 3 (7)
Neither satisfied nor dissatisfied 8 (18)
Satisfied/very satisfied 33 (75)
Would you recommend the cataract surgery and
the new lenses that were put into your eyes to
other people?
No N/A 16 (36)
Yes 28 (64)
N/A Not applicable
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65% of children had myopia [23, 24]. In some regions,
the prevalence of myopia has been reported to be > 80%
[25], which may result from increased time spent per-
forming near-distance work [23]. Consequently, many
people in Korea have worn glasses since childhood, lead-
ing to high expectations for spectacle independence after
cataract surgery. In addition, approximately 33% of
Korean subjects undergoing cataract surgery are aged
< 65 years [19], and this relatively young population
wants to achieve spectacle independence after surgery
for daily intermediate-distance activities such as com-
puter work.
In this study, visual outcomes and safety were evaluated
3months after implantation of the TFNT00 IOL in a
Korean population. The intermediate focal point at 60 cm
was expected to provide optimal intermediate vision for
most subjects in the study, because average arm length is
54 cm. At month 3, the binocular defocus curve showed
that TFNT00 provided vision of approximately 0.1 log-
MAR or better over a full range of defocus, and between
defocus corresponding to distances of 80 to 40 cm,
subjects achieved 0.06 logMAR or better. Study results
showed that the Korean population had similar visual out-
comes compared with those of western populations who
received TFNT00. In a 12-month single-arm trial of 145
subjects in western countries, the mean ± SD best cor-
rected intermediate VA was 0.04 ± 0.12 and 0.08 ± 0.14
logMAR at 60 cm and 80 cm, respectively, and VA of 20/
25 or better was achieved across a range of distances from
4m to 40 cm [15]. In the current study, binocular UCIVA
measured at 60 cm was 0.02 logMAR 1month after IOL
implantation and improved to − 0.03 logMAR by month
3, indicating that TFNT00 provided excellent intermediate
vision. Overall, 90% of Korean subjects achieved 20/25
vision or better at intermediate distance. Approximately
80% of subjects were satisfied with their postoperative
vision, and spectacle independence for intermediate vision
increased from 21% before IOL implantation to 91% after
implantation. This finding suggests that overall subject
satisfaction was improved by better intermediate vision.
In previous comparative clinical trials of TFNT00 with
other trifocal IOLs, TFNT00 showed improved visual
Table 4 Photopic and Mesopic Pupil Size 3 Months Post-






Photopic pupil size, mean (SD), mm 3.84 (0.71) 3.82 (0.84)
Photopic pupil size category, n (%)
Small (≤2.5 mm) 0 2 (5)
Medium (2.5–4 mm) 27 (61) 25 (57)
Large (≥4 mm) 17 (39) 17 (39)
Mesopic pupil size, mean (SD), mm 5.31 (0.95) 5.26 (1.01)
Mesopic pupil size category, n (%)
Small (≤2.5 mm) 0 0
Medium (2.5–4 mm) 4 (9) 3 (7)
Large (≥4 mm) 40 (91) 41 (93)
Fig. 5 Mean manifest refraction spherical equivalent over time after implantation of TFNT00 (all-implanted analysis set). Error bars represent 90%
CI. D = diopter. *At week 1, n = 45 for the first eye.
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outcomes at 60 cm. A study of TFNT00 compared with
the visual performance of Micro F, an earlier-generation
trifocal IOL, showed better VA at 60 cm for subjects
who received TFNT00 (P < 0.05) [14]. Furthermore, VA
at preferred reading distance (approximately 42 cm) was
0.07 ± 0.07 and 0.11 ± 0.08 logMAR for TFNT00 and
Micro F, respectively (P = 0.04) [14]. Similarly, TFNT00
showed improved performance at near distance and at
preferred reading distance compared with the Tecnis
Symfony (Johnson & Johnson) IOL, an extended depth-
of-focus lens [26]. At 40 cm, mean VA was 0.04 ± 0.06
and 0.20 ± 0.06 logMAR for TFNT00 and Symfony, re-
spectively (P < 0.001), and the VA at 60 cm for TFNT00
was 0.06 ± 0.10 logMAR [26], the results of which are
comparable with those reported in the current study. The
results of these studies suggest that TFNT00 may be a
good choice for subjects who want to achieve spectacle in-
dependence at both intermediate and near distances.
In a large multicenter trial conducted in western
countries, binocular UCIVA and UCNVA was better for
subjects who received TFNT00 compared with those who
received AT LISA tri 839MP (P = 0.002 and P = 0.003,
respectively) 6months after IOL implantation [16]. Recent
trials of the AT LISA tri 839MP IOL, which has an inter-
mediate focal point at 80 cm, in Korean subjects showed
that AT LISA tri 839MP provided better VA at intermedi-
ate distances compared with a conventional multifocal
IOL [27]; however, UCIVA was 0.13 logMAR 6months
after implantation of AT LISA tri 839MP [28]. Although
future comparative studies should be conducted for Asian
populations, the results of the current study indicate that
visual outcomes may be improved with TFNT00 com-
pared with AT LISA tri 839MP for subjects in Korea.
Some subjects who receive multifocal IOLs may have
increased visual disturbances and reduced contrast
sensitivity compared with those who receive monofocal
lenses [29]. Overall, the rates of visual disturbances
reported after implantation of TFNT00 in this study
were consistent with those in previous studies [29].
Contrast sensitivity results showed a curve similar to
that reported for healthy young subjects (mean age 21 y)
with normal VA [30], indicating that TFNT00 did not
cause a meaningful reduction in contrast sensitivity.
Additionally, glare did not affect contrast sensitivity
results, and no secondary surgical interventions were re-
quired because of visual disturbances of halo or glare.
Limitations of the present study were the relatively
short follow-up period and lack of a comparison group.
Future trials should evaluate the long-term outcomes,
including subject satisfaction, of TFNT00 in the Korean
population compared with other multifocal lens options
for the correction of presbyopia. Another caveat is that
in this study, we used a standard 60-cm distance to
assess intermediate vision, although the average arm
length in this population is 53–59 cm. Additionally, this
study did not include visual quality measurements such
as mesopic and scotopic contrast sensitivity, halometry,
and ocular aberration; these outcomes should be evalu-
ated in future trials.
Conclusions
In conclusion, this study showed that Korean subjects
who received TFNT00 had functional results across the
full range of distance, particularly from near to inter-
mediate, had good quality of vision at all distances, and
high satisfaction. Overall, the TFNT00 IOL may provide
this population with the best intermediate distance
results compared with other available trifocal IOLs.
Abbreviations
AEs: Adverse events; BCDVA: Best corrected distance visual acuity; cpd: Cycles
per degree; D: Diopter; IOLs: Intraocular lenses; logMAR: Logarithm of the
minimum angle of resolution; MRSE: Manifest refraction spherical equivalent;
Nd:YAG: Neodymium-doped yttrium aluminum garnet; UCDVA: Uncorrected
distance visual acuity; UCIVA: Uncorrected intermediate visual acuity;
UCNVA: Uncorrected near visual acuity; VA: Visual acuity






n (%) E n (%) E
Dry eye 11 (24) 11 10 (23) 10
Glare 10 (22) 10 9 (21) 9
Visual impairment 3 (7) 4 3 (7) 3
Halo vision 3 (7) 3 3 (7) 3
Foreign body sensation in eyes 3 (7) 3 2 (5) 2
Vitreous floaters 2 (4) 2 3 (7) 3
Posterior capsule opacification 1 (2) 1 2 (5) 2
Vision blurred 1 (2) 1 2 (5) 2
Conjunctivitis allergic 1 (2) 1 1 (2) 1
Corneal abrasion 1 (2) 1 1 (2) 1
Corneal edema 1 (2) 1 1 (2) 1
Meibomian gland dysfunction 1 (2) 1 1 (2) 1
Conjunctivitis 1 (2) 1 0 0
Corneal opacity 1 (2) 1 0 0
Device dislocation 0 0 1 (2) 1
Myopia 0 0 1 (2) 1
Optic disc hemorrhage 1 (2) 1 0 0
Photopsia 1 (2) 1 0 0
Surgery 0 0 1 (2) 1
AE Adverse event, E Event, n Number of eyes with an event. a If an eye had
multiple occurrences of an AE, the eye was presented only once in the
respective eye count column for the corresponding AE. Events were counted
each time in the event column. AEs were coded using the Medical Dictionary
for Regulatory Activities Version 21.0
Kim et al. BMC Ophthalmology          (2020) 20:288 Page 10 of 11
Acknowledgements
Medical writing assistance was provided by Catherine DeBrosse, PhD, of
ICON (North Wales, PA), and was funded by Alcon.
Authors’ contributions
TIK, TYC, MJK, KHL, and JYH contributed to the concept and design of the
study, acquisition, analysis and interpretation of the data, drafting and
revising of the manuscript, administrative and technical support, and final
approval of the manuscript. KHL’s contributions also included statistical
analysis and securing funding for this study.
Funding
This study was funded by Alcon Research LLC, Fort Worth, TX, USA, and
Alcon Korea Ltd., Seoul, South Korea. The sponsor participated in study
design; data management, analysis, and interpretation; and funding for the
manuscript preparation.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
This clinical study was conducted under an approved Institutional Review
Board protocol in accordance with the ethical principles of the Declaration
of Helsinki, ISO14155:2011 Clinical Investigation of Medical Devices for Human
Subjects – Good Clinical Practice, and Standards for Medical Devices for Good
Clinical Practice. All subjects provided voluntary written informed consent




TIK is an advisory board member of and has received personal fees from
Hoya Surgical Optics. TYC has nothing to disclose. MJK received grants from
Alcon during the study, and has received personal and consultancy fees
from Alcon unrelated to the present work. KHL was an employee of Alcon
Korea Ltd. during the study. JYH received grants from Alcon Korea Ltd.
during the study.
Author details
1Department of Ophthalmology, Yonsei University College of Medicine,
Seoul, South Korea. 2Department of Ophthalmology, Samsung Medical
Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
3Renew Seoul Eye Clinic, Seoul, South Korea. 4Alcon Korea Ltd, Seoul, South
Korea. 5Department of Ophthalmology, Seoul National University Bundang
Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, South
Korea.
Received: 24 April 2020 Accepted: 6 July 2020
References
1. Javitt J, Brauweiler HP, Jacobi KW, Klemen U, Kohnen S, Quentin CD, et al.
Cataract extraction with multifocal intraocular lens implantation: clinical,
functional, and quality-of-life outcomes. Multicenter clinical trial in Germany
and Austria. J Cataract Refract Surg. 2000;26:1356–66.
2. Vingolo EM, Grenga P, Iacobelli L, Grenga R. Visual acuity and contrast
sensitivity: AcrySof ReSTOR apodized diffractive versus AcrySof SA60AT
monofocal intraocular lenses. J Cataract Refract Surg. 2007;33:1244–7.
3. Kohnen T, Allen D, Boureau C, Dublineau P, Hartmann C, Mehdorn E, et al.
European multicenter study of the AcrySof ReSTOR apodized diffractive
intraocular lens. Ophthalmology. 2006;113:578–84.
4. Alfonso JF, Fernandez-Vega L, Baamonde MB, Montes-Mico R. Prospective
visual evaluation of apodized diffractive intraocular lenses. J Cataract Refract
Surg. 2007;33:1235–43.
5. Bababekova Y, Rosenfield M, Hue JE, Huang RR. Font size and viewing
distance of handheld smart phones. Optom Vis Sci. 2011;88:795–7.
6. Occupational Safety and Health Administration. Working Safely With Video
Display Terminals. OSHA 3092. US Department of Labor; 1997.
7. Gatinel D, Pagnoulle C, Houbrechts Y, Gobin L. Design and qualification of a
diffractive trifocal optical profile for intraocular lenses. J Cataract Refract
Surg. 2011;37:2060–7.
8. Carson D, Hill WE, Hong X, Karakelle M. Optical bench performance of
AcrySof® IQ ReSTOR®, AT LISA® tri, and FineVision® intraocular lenses. Clin
Ophthalmol. 2014;8:2105–13.
9. Kohnen T, Titke C, Bohm M. Trifocal intraocular lens implantation to treat
visual demands in various distances following lens removal. Am J
Ophthalmol. 2016;161:71–7.
10. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor
viewing distance for younger and older workers. Proc Hum Factors Ergon
Soc Annu Meet. 2008;52:1614–7.
11. Kohnen T. First implantation of a diffractive quadrafocal (trifocal) intraocular
lens. J Cataract Refract Surg. 2015;41:2330–2.
12. AcrySof IQ PanOptix Presbyopia-Correcting IOL. Product Information. Forth
Worth: Alcon Laboratories, Inc.; 2015.
13. Carson D, Xu Z, Alexander E, Choi M, Zhao Z, Hong X. Optical bench performance
of 3 trifocal intraocular lenses. J Cataract Refract Surg. 2016;42:1361–7.
14. Gundersen KG, Potvin R. Trifocal intraocular lenses: a comparison of the
visual performance and quality of vision provided by two different lens
designs. Clin Ophthalmol. 2017;11:1081–7.
15. Bala C, Martinez AA, Kohnen T. Multicenter visual outcomes evaluation of a
new trifocal presbyopia correcting IOL – 12 month results. Presented at:
American Society of Cataract and Refractive Surgery, April 13-17, 2018..
Washington, DC.
16. Lapid-Gortzak R, Martinez A. Multicenter clinical investigation of visual
function after bilateral implantation of two presbyopia-correcting trifocal
IOLs [abstract]. Presented at: European Society of Cataract and Refractive
Surgeons, September 22-26, 2018. Vienna; 2018.
17. Ahn JH, Kim DH, Shyn KH. Investigation of the changes in refractive surgery
trends in Korea. Korean J Ophthalmol. 2018;32:8–15.
18. Lee Y. Estimation of body size and growth patterns in Korean boys. J
Physiol Anthropol. 2015;34:20.
19. Korean Statistical Information Service. Available at: http://kosis.kr/eng/index/
index.do. Accessed 21 June 2019.
20. Pager CK. Expectations and outcomes in cataract surgery: a prospective test
of 2 models of satisfaction. Arch Ophthalmol. 2004;122:1788–92.
21. Monaco G, Gari M, Di Censo F, Poscia A, Ruggi G, Scialdone A. Visual performance
after bilateral implantation of 2 new presbyopia-correcting intraocular lenses: trifocal
versus extended range of vision. J Cataract Refract Surg. 2017;43:737–47.
22. Lee DC, Lee SY, Kim YC. An epidemiological study of the risk factors
associated with myopia in young adult men in Korea. Sci Rep. 2018;8:511.
23. Han SB, Jang J, Yang HK, Hwang JM, Park SK. Prevalence and risk factors of myopia
in adult Korean population: Korea national health and nutrition examination survey
2013-2014 (KNHANES VI). PLoS One. 2019;14:e0211204.
24. Lim DH, Han J, Chung TY, Kang S, Yim HW. Epidemiologic survey
Committee of the Korean Ophthalmologic Society. The high prevalence of
myopia in Korean children with influence of parental refractive errors: the
2008-2012 Korean National Health and nutrition examination survey. PLoS
One. 2018;13:e0207690.
25. Lee JH, Jee D, Kwon JW, Lee WK. Prevalence and risk factors for myopia in a
rural Korean population. Invest Ophthalmol Vis Sci. 2013;54:5466–71.
26. Ruiz-Mesa R, Abengozar-Vela A, Ruiz-Santos M. A comparative study of the
visual outcomes between a new trifocal and an extended depth of focus
intraocular lens. Eur J Ophthalmol. 2018;28:182–7.
27. Yu S, Kim YI, Ha SW, Lee GJ, Lee KW, Park YJ. Comparison of the visual outcomes
after cataract surgery with implantation of a bifocal and trifocal diffractive intraocular
lens. J Korean Ophthalmol Soc. 2016;57:405–12.
28. Kwon YK, Kim HK, Lee JH. Clinical outcomes of diffractive trifocal
intraocular lens in both eyes: a 6-month follow-up. J Korean
Ophthalmol Soc. 2015;56:1331–7.
29. de Silva SR, Evans JR, Kirthi V, Ziaei M, Leyland M. Multifocal versus
monofocal intraocular lenses after cataract extraction. Cochrane Database
Syst Rev. 2016;12:CD003169.
30. Koefoed VF, Baste V, Roumes C, Hovding G. Contrast sensitivity measured
by two different test methods in healthy, young adults with normal visual
acuity. Acta Ophthalmol. 2015;93:154–61.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kim et al. BMC Ophthalmology          (2020) 20:288 Page 11 of 11
